Current Coverage Archives

Three Scientists Win Nobel for Unlocking the Immune System’s Self-Control – ( $IBB $XBI )

by Vista Partners LLC October 16, 2025 408Views 0Likes

A Discovery That Redefined Immunity The 2025 Nobel Prize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for breakthroughs that revealed how the immune system prevents itself from turning on the body—a discovery that…

Biotech Rebound: Praxis Precision Medicines Delivers Stunning Clinical Turnaround -( $PRAX $IBB $XBI )

by Vista Partners LLC October 16, 2025 554Views 0Likes

Praxis Precision Medicines’ (PRAX) stock erupted Thursday up greater than 200% currently after the company reported decisive Phase 3 results for its essential tremor drug, sending shares to an all-time high and erasing months of skepticism. Breakthrough Data Revives a Struggling Program…

Novo Nordisk Strikes $2.1 Billion Deal with Omeros, Expanding Rare Disease Portfolio – ( $NVO $OMER $IBB $XBI )

by Vista Partners LLC October 15, 2025 601Views 0Likes

Novo Nordisk (NVO, $56.70, +.05%) and Omeros Corporation (OMER $10.52, +157%) unveiled a sweeping asset purchase and license agreement Wednesday, catapulting the Danish diabetes powerhouse deeper into rare disease territory with a potential $2.1 billion pact for Omeros’ experimental MASP-3 inhibitor, zaltenibart.…

Investors Eye Eupraxia’s Breakthroughs as Tribe Public Brings CEO to the Forefront -( $EPRX $IBB $XBI )

by Vista Partners LLC October 10, 2025 485Views 0Likes

Tribe Public’s next CEO Presentation and Q&A Webinar Event is scheduled for Tuesday, October 14 at 9 a.m. Pacific, spotlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX) at a critical juncture in its development. The virtual event, titled “How New Drug Delivery Methods Are Changing…

Bristol Myers Squibb Doubles Down on Innovation With Orbital and RayzeBio Acquisitions -( $BMY $IBB $XBI )

by Vista Partners LLC October 10, 2025 533Views 0Likes

Bristol Myers Squibb’s (BMY) $4.1 billion acquisition of RayzeBio signaled a bold strategic leap into radiopharmaceuticals, but today’s headline-grabbing purchase of Orbital Therapeutics for $1.5 billion crystallizes the pharma giant’s wider ambition: to own the next frontier in oncology and immune therapies…

Game Changer for Immunocompromised? GeoVax Makes Case at World Vaccine Congress Europe 2025 -( $GOVX $IBB $XBI )

by Vista Partners LLC October 9, 2025 604Views 0Likes

GeoVax Labs (NASDAQ: GOVX) is advancing its multi-antigen COVID-19 vaccine, GEO-CM04S1, with fresh clinical data set to take center stage at the World Vaccine Congress Europe 2025, Europe's largest vaccine event, held October 13-16 at the RAI Amsterdam Convention Centre in…

Modular Medical Appoints Insulin Pump Veteran, Eyes Aggressive Global Rollout for Pivot Device – ( $MODD $PODD )

by Vista Partners LLC October 7, 2025 554Views 0Likes

Modular Medical (NASDAQ: MODD) is entering a transformational phase with the appointment of David Bosshard as Head of International Operations, marking the company’s most ambitious push toward global expansion and market leadership in diabetes care technology. Bosshard’s proven expertise in scaling European…

Amarin Corporation (NASDAQ: AMRN): Deep Value or Hidden Catalyst? ( $AMRN $IBB $XBI )

by Vista Partners LLC October 3, 2025 470Views 0Likes

Amarin Corporation (NASDAQ: AMRN), a company that envisions a world where cardiovascular disease is NOT the leading cause of death worldwide, seemingly presents itself as a deep-value opportunity, trading near its cash value yet is believed to be poised for a turnaround…

Virtual Health Giant Teladoc Rallies On Thursday After Snapping Up Acquisitions in ’25 – ( $TDOC $AMWL $DOCS $EVH )

by Vista Partners LLC October 2, 2025 612Views 0Likes

Teladoc Health (TDOC) shares are is surging today. On Aug, 14 Teledoc, the global leader in virtual care, announced an acquisition of Telecare, an Australian pioneer in virtual specialist and allied health services—a move celebrated by Wall Street as turbocharging Teladoc’s…

Eupraxia Pharmaceuticals Interest Surges With Craig-Hallum Price Target Boost, Clinical Milestones, and Pipeline Expansion -( $EPRX $BMY $AZN $SNY )

by Vista Partners LLC October 2, 2025 551Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is drawing fresh investor attention as Craig-Hallum raises its price target to $14 following a series of noteworthy pipeline updates and recent clinical trial momentum for its lead asset, EP-104GI, targeting eosinophilic esophagitis (EoE) and broader gastrointestinal indications.…

Current Coverage

Your Guide To Staying Informed In The Markets